Krazati

(Adagrasib)

Krazati

Drug updated on 11/15/2023

Dosage FormTablet (oral; 200 mg)
Drug ClassRAS GTPase inhibitors
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), as determined by an FDA approved test, who have received at least one prior systemic therapy.

Product Monograph / Prescribing Information

Document TitleYearSource
Krazati (adagrasib) Prescribing Information.2022Mirati Therapeutics, Inc. 3545 Cray Court San Diego, CA

Systematic Reviews / Meta-Analyses